Advances in bone marrow mesenchymal stem cell transplantation for treatment of glaucomatous optic neuropathy

Authors: Wang Shujing,  Shao Zhengbo
DOI: 10.3760/cma.j.cn115989-20200302-00131
Published 2020-10-10
Cite as Chin J Exp Ophthalmol, 2020,38(10): 881-884.

Abstract                              [View PDF] [Read Full Text]

Glaucoma is a disorder that leads to retinal ganglion cells (RGCs) apoptosis, visual field loss and optic nerve degeneration.The RGCs death is irreversible, which limites their ability for axon regeneration after injury.Bone marrow mesenchymal stem cells (BMSCs) have shown promise as cell-incorporation, cell-supplements and paracrine-mediated therapy for compromised neurons, which have allowed the possibility of the pluripotent BMSCs based regeneration of retinal cells and repair of neurodegenerative diseases.Intravitreal injection, subretinal injection and autologous BMSCs homing transplantation were explored as therapy for various retinal injury conditions.These BMSCs primarily have paracrine trophic effects and can also incorporate into the damaged retina directly, which have regenerative and protective effects on the reduce of RGCs apoptosis and retinal nerve fiber loss, and multiple cell signals and mechanisms are involved.This review provides an update of the current evidence of BMSCs as treatment and potential limitations, and complications for glaucomatous RGCs dysfunction.The researches including induced-differentiation, transplantation methods and the potential neuroprotective mechanism of BMSCs as therapy for glaucomatous retinal degeneration were discussed.

Key words:

Glaucoma; Bone marrow-derived stem cell; Retinal ganglion cell; Optic nerve; Cell transplantation

Contributor Information

Wang Shujing
Department of Ophthalmology, the Second Affiliated Hospital of Harbin Medical University, The Key Laboratory of Myocardial Ischemia, Harbin Medical University, Ministry Education, Future Medical Laboratory, the Second Affiliated Hospital of Harbin Medical University, Harbin 150086, China
Shao Zhengbo
Department of Ophthalmology, the Second Affiliated Hospital of Harbin Medical University, The Key Laboratory of Myocardial Ischemia, Harbin Medical University, Ministry Education, Future Medical Laboratory, the Second Affiliated Hospital of Harbin Medical University, Harbin 150086, China
(Read 233 times, 1 visits today)
Updated: December 26, 2022 — 2:32 am